Mereo BioPharma Group (LON:MPH) Sets New 52-Week Low at $48.00

Shares of Mereo BioPharma Group PLC (LON:MPH) reached a new 52-week low during trading on Friday . The company traded as low as GBX 48 ($0.63) and last traded at GBX 48 ($0.63), with a volume of 13918 shares changing hands. The stock had previously closed at GBX 50 ($0.65).

The company has a quick ratio of 2.05, a current ratio of 2.13 and a debt-to-equity ratio of 65.56. The stock has a market capitalization of $47.02 million and a P/E ratio of -1.07. The stock’s 50 day moving average price is GBX 72.87.

In other news, insider Anders Ekblom acquired 46,700 shares of Mereo BioPharma Group stock in a transaction on Tuesday, May 7th. The stock was bought at an average cost of GBX 109 ($1.42) per share, with a total value of £50,903 ($66,513.79). Also, insider Peter J. Fellner acquired 30,000 shares of Mereo BioPharma Group stock in a transaction on Monday, April 29th. The shares were purchased at an average cost of GBX 128 ($1.67) per share, with a total value of £38,400 ($50,176.40).

Mereo BioPharma Group Company Profile (LON:MPH)

Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease.

Further Reading: Overbought

Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.